Explore more publications!

Press Releases

Openwater’s Open-LIFU Device Supports Concierge Mental Health Research with TIESA
K2G Holding AG to Be Listed on the Vienna Stock Exchange, Advancing AI Agents for the Insurance Industry
BCYW Foundation Begins 2026 First Global Scientific Webinar Advancing Breast Cancer Research and Care for Young Women
Investments in Colorless Polyimide Films Market for 2026
TIUA Appoints Dr. Janice Crenshaw as Director of Pastoral Care, Clinical Ethics & Doctoral Research Oversight
CRITICAL METALS CORP NASDAQ-CRML Acquires an Integrated Rare Earth Element Assay Analysis Lab Facility to Support Faster Drilling Assay Results for 2026 Drilling Campaign at Tanbreez
Digital Manufacturing in Life Sciences Market to Reach USD 177.5 Billion by 2035, Leading at 15.6% CAGR by 2035
Komet Irrigation Invests in Data, Technology, and Farmers’ Future
New Research in Scientific Reports Shows Infants Recognize When Others Need Information
AOP Health’s Rapiblyk™ Now Accessible via Leading US Healthcare Improvement Companies
TOP200 NAWA - the Polish National Agency for Academic Exchange invites oustanding research talents to Poland
United Cerebral Palsy’s 2026 “Change is Possible for CP” Grant Program Now Accepting Applications
ColonBroom GLP-1 Booster Ingredients Investigated: 2026 Consumer Analysis Examines Colon Broom GLP-1 Formulation Disclosures
Best Over The Counter GLP-1 Booster (2026) Search Trends: ColonBroom GLP-1 Booster Ingredient Transparency and Consumer Analysis
Bart Crebolder Leads AI Analytics Launch on Aussie Casinos and Spil Uden Om ROFUS Platforms
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
Castellum, Inc. Announces the Award of a $49.8 Million Recompete Contract to its SSI Subsidiary
Quick Custom Intelligence Brings Live, Next-Gen AI to ICE Barcelona 2026 with Modulus
Trends and Demand in Thermoformed Trays Market 2025-35
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions